Dianthus Therapeutics (NASDAQ:DNTH) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research report report published on Monday,Benzinga reports. The firm currently has a $40.00 price target on the stock. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q4 2024 earnings at ($1.14) EPS, FY2024 earnings at ($3.06) EPS, Q1 2025 earnings at ($1.21) EPS, Q2 2025 earnings at ($1.29) EPS, Q3 2025 earnings at ($1.06) EPS, Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($4.47) EPS, FY2026 earnings at ($4.89) EPS, FY2027 earnings at ($4.61) EPS and FY2028 earnings at ($3.94) EPS.

DNTH has been the topic of a number of other reports. Robert W. Baird assumed coverage on shares of Dianthus Therapeutics in a report on Friday, July 26th. They issued an “outperform” rating and a $58.00 price target on the stock. Wedbush decreased their price objective on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Raymond James boosted their target price on Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Oppenheimer increased their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday. Finally, Baird R W upgraded Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $46.43.

Dianthus Therapeutics Trading Down 3.3 %

NASDAQ DNTH opened at $25.49 on Monday. Dianthus Therapeutics has a 52-week low of $6.58 and a 52-week high of $33.77. The firm’s 50 day moving average price is $27.65 and its 200-day moving average price is $26.63.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million. As a group, research analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of large investors have recently bought and sold shares of DNTH. Vanguard Group Inc. raised its holdings in shares of Dianthus Therapeutics by 250.0% during the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after purchasing an additional 384,182 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Dianthus Therapeutics by 860.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock valued at $2,095,000 after buying an additional 72,509 shares during the period. SG Americas Securities LLC boosted its stake in shares of Dianthus Therapeutics by 104.0% in the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock worth $242,000 after buying an additional 4,506 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its stake in shares of Dianthus Therapeutics by 281.9% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company’s stock worth $1,022,000 after buying an additional 29,159 shares during the last quarter. Finally, American Century Companies Inc. raised its position in Dianthus Therapeutics by 38.6% during the second quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock valued at $788,000 after acquiring an additional 8,473 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.